Involvement of the Physician in Primary Prevention and Pre-hospital Management of Stroke

Stroke Clinical Trial

— PREVENTION AVC  

Official title:

Involvement of the Physician in Primary Prevention and Pre-hospital Management of Stroke

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03975218
• Other study ID #: PREVENTION AVC
• Status: Completed
• Start date: June 7, 2019
• Est. completion date: December 5, 2019

Study information

• Verified date: December 2019
• Source: Groupe Hospitalier Paris Saint Joseph
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Stroke is a growing disease. It is the first pathology responsible for acquired handicap, the second of dementia and the second cause of death in the world. In France, they are the leading cause of death in women and the third cause in men. Sequelae and disabilities also represent a significant financial cost for health insurance.

The early management of the treatment improves the patient's vital and functional prognosis. The ability of the patient to identify the signs of stroke requiring urgent consultation and proper orientation are therefore crucial for further management.

The most common signs that patients must recognize are muscle weakness or sudden paralysis of an arm, leg or half of the body, asymmetry of the face, tingling, numbness of a hemi-body, speech or understanding, loss of vision of an eye or hemifield, disorder of the coordination of a hemi-body. The variety of clinical pictures complicates primary prevention.

In this context, a 2010-2014 National Stroke Action Plan was undertaken with the aim, among other things, of developing information to prevent stroke and to limit its sequelae. In this plan, the attending physician must improve prevention in high-risk patients and be a link between the city and the hospital for follow-up.

Several questions arise:

• Are patients who are regularly followed by a general practitioner better educated on the signs of stroke / TIA and thus more able to give an appropriate warning?

• What is the profile of patients who have not been affected by the different modes of primary prevention?

• What are the effective means of information and those desired

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: December 5, 2019
• Est. primary completion date: July 29, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient whose age is = 18 years

• Patient hospitalized in the neurology / neurovascular department within the GHPSJ following a stroke (first episode or recurrence)

• Francophone patient

Exclusion Criteria:

• Patient with previously labeled cognitive impairment

• Patient under tutorship or curatorship

• Patient deprived of liberty

• Patient unable to answer the questionnaire

• Patient opposing participation in the study

Related Conditions & MeSH terms

• Stroke

Intervention

Other:
• Patients With Stroke
In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.

Locations

Country	Name	City	State
France	Groupe Hospitalier Paris Saint-Joseph	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time until patient's care in the hospital after stroke's symptoms	The delay between the observation of signs of stroke and specialized neurovascular management at the hospital will be measured. This measures the impact of physician's prevention on the management of stroke.	Day 1
Secondary	Study the different effective means of primary prevention	Patient questionnaire corresponds to open question about physician in primary prevention and pre-hospital management of stroke to which the patient will respond yes or no.	Day 1